secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001493152-26-006227
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ernexa Therapeutics prices $10.5M public offering of 21M shares and warrants
----------------------------------------------------------------------------

- Offering of 21M shares of common stock (or equivalents) and warrants to buy 21M shares at $0.50 per unit.
- Gross proceeds expected ~$10.5M; net proceeds for development programs, working capital, and general purposes.
- Warrants exercisable at $0.68/share, expire 5 years from issuance or 180 days after release of Phase 1 ERNA-101 data.
- Brookline Capital Markets acted as exclusive placement agent; offering closed Feb 10, 2026.
- Potential additional $14.3M if all warrants exercised on cash basis (no assurance given).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000149315226006227/0001493152-26-006227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000149315226006227/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-006227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer